Report of Foreign Issuer (6-k)

Date : 08/29/2019 @ 12:29PM
Source : Edgar (US Regulatory)
Stock : Akari Therapeutics PLC (AKTX)
Quote : 1.8032  0.0 (0.00%) @ 8:59AM

Report of Foreign Issuer (6-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

August 2019

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x       Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

 

 

CONTENTS

 

On August 29, 2019, Akari Therapeutics, Plc (the “Company”) issued unaudited interim condensed consolidated financial statements as of June 30, 2019, prepared in accordance with generally accepted accounting principles in the United States, together with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operations for the same period. Attached hereto and incorporated by reference herein are the following exhibits:

 

99.1 Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2019
99.2 Management Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2019

 

In addition, on August 29, 2019, the Company issued a press release announcing its second quarter 2019 financial results and recent clinical progress highlights. A copy of the press release is attached hereto as Exhibit 99.3 and incorporated herein by reference.

 

The information contained in Exhibits 99.1 and 99.2 and the statements under “Second Quarter 2019 Financial Results”, the accompanying financial statements and “Cautionary Note Regarding Forward-Looking Statements” of Exhibit 99.3 are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

  

Exhibit No.

 

99.1 Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2019
   
99.2 Management Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2019
   
99.3

Press release dated August 29, 2019

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc  
  (Registrant)  
       
  By: /s/ Clive Richardson  
  Name:   Clive Richardson  
    Chief Executive Officer and Chief Operating Officer  

 

Date: August 29, 2019

 

 

 

Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Akari Therapeutics Charts.

Akari Therapeutics (NASDAQ:AKTX)
Intraday Stock Chart

Today : Tuesday 19 November 2019

Click Here for more Akari Therapeutics Charts.

Latest AKTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.